Trial Profile
A retrospective study to evaluate the effectiveness of ferric carboxymaltose in patients with iron deficiency anaemia secondary to gastrointestinal chronic blood loss
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Jun 2017
Price :
$35
*
At a glance
- Drugs Ferric carboxymaltose (Primary)
- Indications Iron deficiency anaemia
- Focus Therapeutic Use
- 16 Jun 2017 New trial record